SIGLEC1 as a novel prognostic factor is regulated by Yiqi Huayu Jiedu Decoction in colorectal cancer.

We studied the prognostic value of SIGLEC1 in colorectal cancer (CRC) using bioinformatics. SIGLEC1 exhibited differential expression between the tumor and control samples, and improved survival was observed in patients with increased SIGLEC1 expression. The univariate and multivariate analyses confirmed SIGLEC1 as an independent prognostic factor for CRC, based on which a nomogram was constructed for predicting survival in patients with CRC. Additionally, higher SIGLEC1 expression was correlated with increased immunological/stromal/ESTIMATE scores as well as immune cell infiltration and was strongly and positively associated with T helper cells and macrophages. Furthermore, significant positive correlations were observed between SIGLEC1 expression and inhibitory/coinhibitory immunological genes. Additionally, the TIDE results of patients with CRC showed that increased SIGLEC1 expression was related to poorer immunotherapeutic responses. In clinical samples from patients with CRC, a decrease in SIGLEC1 expression was noted compared to para-cancerous tissues and samples from patients who received Yiqi Huayu Jiedu Decoction (YHJD) treatment. The in vivo results indicated the superior efficacy of YHJD against CRC in inhibiting tumor metastasis. Our study demonstrates that SIGLEC1 serves as a prognostic factor for CRC, strongly linked to immune response, and can be modulated by YHJD, suggesting novel avenues for CRC treatment.